Back to Agenda
Session 3 Track 2: Advances in Oligonucleotide Delivery
Session Chair(s)
Arthur A. Levin, PhD
Distinguished Scientist, Avidity Biosciences, United States
Philip Gatti, PhD
Pharmacologist, FDA, United States
This session will explore three novel areas of delivery. Oral, lipid conjugated siRNA-dimers and synthetic exosomes. The goal of the session is to consider a small fraction of the diversity of technologies which can be utilized to overcome the challenges of moving highly water-soluble nucleic acid therapeutics through cell membranes to produce pharmacologic activity.
This session should address key questions like- how broadly applicable is this technology across the different modalities of oligonucleotide therapeutics? Does this modality enhance the therapeutic index of a compound? Is this delivery modality amenable to multiple cell and tissue types?
Speaker(s)
Sriram Sathyanarayanan, PhD, MSc
Chief Scientific Officer, Codiak Biosciences , United States
Exosome Mediated Genetic Reprogramming of Tumor Associated Macrophages by exoASO-STAT6
Stefan McDonough, PhD
Vice President, Neuroscience, Atalanta, United States
Branched siRNA for Broad and Durable Target Silencing in the CNS
Scott Henry, PhD
Senior Vice President, Nonclinical Development, Ionis Pharmaceuticals, Inc., United States
Recent Efforts in the Oral Delivery of GalNAc-Conjugated ASOs
Have an account?